Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs …

The emergence of antimicrobial resistance against Mycobacterium tuberculosis, the leading
cause of mortality due to a single microbial pathogen worldwide, represents a growing threat …

Background: The American Thoracic Society, US Centers for Disease Control and
Prevention, European Respiratory Society, and Infectious Diseases Society of America …

Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a
combination of multiple second-line drugs. These drugs are associated with numerous …

Background Bedaquiline and delamanid are the first drugs of new classes registered for
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …

Objective To produce pooled estimates of the global results of tuberculosis (TB) treatment
and analyze the predictive factors of successful TB treatment. Methods Studies published …

Background The development of drug-resistant (DR) tuberculosis (TB) has become an
increasing concern over the past few decades as the result of numerous factors, including …

We assessed the effectiveness and safety of standardised, shorter multidrug-resistant
tuberculosis (MDR-TB) regimens by pooling data from observational studies. Published …

We sought to compare the effectiveness of two World Health Organization (WHO)-
recommended regimens for the treatment of rifampin-or multidrug-resistant (RR/MDR) …

Rationale: Bedaquiline and delamanid offer the possibility of more effective and less toxic
treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however …